In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells

Erika Nordberg, A. Orlova, M. Friedman, V. Tolmachev, S. Ståhl, F. Y. Nilsson, B. Glimelius, J. Carlsson

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

The epidermal growth factor receptor, EGFR, is overexpressed in many carcinomas. Targeting this receptor with radionuclides is important for imaging and therapy applications in nuclear medicine. We investigated the in vitro and in vivo properties of a new high affinity EGFR binding affibody molecule, (ZEGFR:955)2, when conjugated with CHX-A″-DTPA and labelled with 111In. The binding time patterns and retention studies were performed using cultured squamous carcinoma A431 cells that overexpress EGFR. In the in vivo studies, female BALB/c nu/nu mice carrying tumours from xenografted A431 cells were used. The in vitro studies showed EGFR specific binding, high uptake and good retention of 111In when delivered as [111In](ZEGFR:955)2. The retention after 72 h of incubation was 38.0±1.15% of the initial level. The biodistribution study showed a tumour specific 111In uptake of 3.8±1.4% of injected dose per gram tumour tissue 4 h post-injection. The tumour to blood ratio was 9.1 and the tumours could easily be visualized with a gamma camera at this time-point. 111In delivered with [111In](ZEGFR:955)2 gave an EGFR specific uptake and the results indicated that the (ZEGFR:955)2 affibody molecule is a candidate for radionuclide-based tumour imaging. Potential therapy applications are discussed.

Original languageEnglish
Pages (from-to)853-857
Number of pages5
JournalOncology Reports
Volume19
Issue number4
DOIs
Publication statusPublished - Apr 2008
Externally publishedYes

Keywords

  • A431
  • Affibody molecule
  • EGFR
  • Mouse
  • Radionuclide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'In vivo and in vitro uptake of <sup>111</sup>In, delivered with the affibody molecule (Z<sub>EGFR:955</sub>)<sub>2</sub>, in EGFR expressing tumour cells'. Together they form a unique fingerprint.

Cite this